Table 5.
Complications and Management of Patients with COVID-19
| n (%) (n = 85) | |
|---|---|
| Complications | |
| Respiratory failure | 80 (94.1) |
| Shock | 69 (81.2) |
| ARDS | 63 (74.1) |
| Arrhythmia | 51 (60) |
| Acute cardiac injury | 38 (44.7) |
| Acute liver injury | 30 (35.3) |
| Sepsis | 28 (32.9) |
| Treatment | |
| Oxygen therapy | 57 (67.1) |
| Noninvasive mechanical ventilation | 61 (71.8) |
| Invasive mechanical ventilation | 18 (21.2) |
| Kidney replacement therapy | 8 (9.4) |
| ECMO | 0 |
| Antibiotic treatment | 77 (90.6) |
| Antifungal treatment | 11 (12.9) |
| Antiviral treatment | 78 (91.8) |
| Glucocorticoids | 65 (76.5) |
| IFN | 33(38.8) |
| Intravenous immunoglobulin therapy | 38 (44.7) |
| COVID-19 recovery patient plasma treatment | 1(1.2) |
| Antiinfection treatment | |
| Antibiotics | |
| Meropenem | 38 (44.7) |
| Imipenem/cilastatin | 1 (1.2) |
| Moxifloxacin | 40 (47.1) |
| Levofloxacin | 4 (4.7) |
| Linezolid | 18 (21.2) |
| Vancomycin | 2(2.4) |
| Teicoplanin | 2 (2.4) |
| Tigecycline | 2 (2.4) |
| Piperacillin/tazobactam | 9 (10.6) |
| Ceftriaxone sodium | 3 (3.5) |
| Cefoperazone/sulbactam | 2 (2.4) |
| Ceftazidime tazobactam | 2(2.4) |
| Antiviral | |
| Arbidol hydrochloride capsules | 51 (60) |
| Lopinavir and ritonavir tablets | 11 (12.9) |
| Oseltamivir | 9 (10.6) |
| Paramivir | 6 (7.1) |
| Ganciclovir | 5 (5.9) |
| Ribavirin | 4 (4.7) |
| Antifungal | |
| Caspofungin | 2 (2.4) |
| Voriconazole | 8 (9.4) |
| Fluconazole | 3 (3.5) |
Definition of abbreviations: ARDS = acute respiratory distress syndrome; COVID-19 = coronavirus disease; ECMO = extracorporeal membrane oxygenation.